VigiLanz Launches Intelligent Event Reporting Suite, Expands #1 Rated Clinical Surveillance Platform Impacting Patient Safety, Risk, Compliance, and Patient Relations

Automated event detection, expedited documentation, and enterprise-wide visibility help hospitals and health systems improve safety and reduce risks

MINNEAPOLIS, April 7, 2021VigiLanz, a clinical surveillance company, today announced the launch of three new event reporting solutions built on VigiLanz’s award-winning enterprise software platform. The new solutions, VigiLanz Risk and Claims, VigiLanz Compliance, and VigiLanz Patient Relations, complement VigiLanz’s existing Dynamic Safety Surveillance product to expand the platform’s benefits and improve hospitals’ bottom line by enabling them to quickly capture, monitor, and act on information, enhancing patient safety and reducing organizational risk.

Recently recognized as Best in KLAS for Infection Control and Monitoring and Pharmacy Surveillance, VigiLanz applied its more than 20 years of complex, clinical data experience to create and integrate the new solutions, which help hospitals harness their own data to make safety improvements and reduce risks. Key capabilities include automated event capture; expedited documentation through form autopopulation; and enhanced visibility into events and improvement opportunities through deep integration that results in data-rich enterprise dashboards.

“In order for hospitals to foster an overarching culture of safety, risk mitigation must be addressed for patients, visitors, and employees,” said Stacy Pur, VigiLanz’s VP of Product Development. “These solutions create a canopy of protection for hospitals and their patients. This allows a system-wide approach to reducing risks and improving patient satisfaction, while also saving time. Enhanced visibility, highly targeted notifications, expedited documentation, and easy escalation processes are just a few of the benefits hospitals will experience.”

Want more information on our event reporting solutions?

About the solutions:

VigiLanz Dynamic Safety Surveillance
VigiLanz optimizes safety event reporting through real-time alerts, auto-detection of events, comprehensive management and investigation tools, automated escalation, and a full library of analytics and reporting capabilities.

VigiLanz Risk and Claims
VigiLanz streamlines workflows throughout the entire lifecycle of claims and litigation events and identifies risk-reduction and damage-control opportunities. Key benefits include the ability to easily enter, manage, and escalate claims and budgets; analyze department-specific and enterprise-wide data; and continuously improve by mitigating risks and preventing future incidents.

VigiLanz Compliance
VigiLanz helps prevent, detect, and resolve illegal or unethical conduct and promotes a culture of ethical practice. Features include automated violation notifications, comprehensive management and escalation tools, and department-specific and enterprise-wide reports and analytics.

VigiLanz Patient Relations
VigiLanz streamlines the management of patient and visitor feedback, identifies patient satisfaction improvement and service recovery opportunities, and optimizes value-based reimbursement through simplified workflows, escalation tools, and enterprise-wide reporting.

“The event reporting solutions could not have been launched at a better time, as hospitals are working tirelessly to improve care during the COVID-19 pandemic and implement lessons learned from it,” said David Goldsteen, VigiLanz’s CEO. “We’re proud of our ability to continually raise the bar for clinical surveillance, and put it into the hands of more healthcare workers. We’re supporting more efficient workflows and maximizing their resources, while also helping them improve care and reduce risks.”

Learn more about the new and expanded solutions at VigiLanzcorp.com.

VigiLanz earned Best in KLAS in the “2021 Best in KLAS: Software and Services” report, released February 2, 2021. Over the past four years, VigiLanz has earned 10 KLAS awards for its solutions.

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

VigiLanz Ranked No. 1 by KLAS Research for Infection Control and Monitoring and Pharmacy Surveillance for Fourth Straight Year

The clinical surveillance company most trusted by hospitals is recognized as Best in KLAS, totaling 10 KLAS awards over 4 consecutive years

MINNEAPOLIS – Feb. 2, 2021 – VigiLanz, a clinical surveillance company, today announced that it has earned 2021 Best in KLAS designations from KLAS Research for Infection Control and Monitoring and Pharmacy Surveillance. This is the fourth year VigiLanz has been recognized by KLAS as a leader across both areas, and brings its total count of KLAS awards to 10. VigiLanz was also recognized in previous years in the Antimicrobial Stewardship category, which KLAS folded into Pharmacy Surveillance this year.

VigiLanz products earned Best in KLAS across two segments in the “2021 Best in KLAS: Software and Services” report, released on February 2:

Infection Control and Monitoring

Earning a score of 93.7, VigiLanz’s Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s EHR. Its exception-based alert system puts all patient records under continuous surveillance to alert decision makers in real time of potential infections, MDROs, isolation candidates, organism clusters, conditions of concern, and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

“VigiLanz has been really good through the COVID-19 crisis because every time we need a new test, I just email the vendor, and they add it to the product. The vendor’s help has been a blessing.”

  • Physician, August 2020, klasresearch.com

Pharmacy Surveillance

Earning a score of 91.1, VigiLanz’s Dynamic PharmacoVigilance product acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for adverse drug event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, it automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

“The product is extremely easy to use, and that has to be a big part of our success. Something that is hard to use or clunky wouldn’t work for our teams’ workflow. It doesn’t matter how good the quality of the material is; a clunky product wouldn’t work because we are moving at such a fast pace.

  • Manager, June 2020, klasresearch.com

In addition, VigiLanz’s Antimicrobial Stewardship product monitors antimicrobial therapy to ensure appropriate use, including unnecessary antibiotic therapy, de-escalation opportunities, positive rapid diagnostic test results, drug-bug mismatches, and opportunities for antibiotic “time-outs.” The Antimicrobial Stewardship dashboard shows usage and resistance trends across the organization, is Meaningful Use 3 certified, and is certified by the National Healthcare Safety Network for easy, direct reporting on antibiotic use.

“I have found VigiLanz to be really helpful with their ability to fine-tune a rule and screen out a lot of noise. So we are getting exactly what we need. We can tease out geography, look at specific organisms, or look at different time frames. This is very powerful and very easy to do in the system.”

  • Director, January 2020, klasresearch.com

“In what’s proven to be a particularly challenging year for our hospital customers, we’re extremely proud to continue our recognition by KLAS four years in a row,” said VigiLanz Chairman and CEO David Goldsteen, MD. “We know our customers rely on us when they need it most—whether that’s triaging COVID-19 cases, monitoring the use of specific pharmaceuticals during a shortage, or saving clinicians time providing real-time alerts and reports so they can focus more on patients. It’s our job to help hospitals keep patients safe, and we’re honored to see the glowing feedback from this past year.”

Best in KLAS is a recognition given to vendors for outstanding efforts to help healthcare professionals deliver better patient care. The Best in KLAS designation is reserved for the software and services market segments that have the broadest operational and clinical impact on healthcare organizations. Rankings are based on customer surveys of North American healthcare leaders, administrators, clinicians, and others who interact with the solutions.

Selected commentary collected about VigiLanz Infection Control and Monitoring and Pharmacy Surveillance, January 2021  © 2021 KLAS. Visit klasresearch.com for a complete view.

###

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

Freeman Medical Focus – KSN Fourstates News | VigiLanz

Freeman Health System, which is based in Joplin, Missouri and serves an area of 450,000 people across Missouri, Arkansas, Kansas, and Oklahoma, has been using VigiLanz since 2018 to enhance their antimicrobial stewardship processes. In an interview with KSN Fourstates Homepage, Adrienne Carey, Clinical Pharmacist, and Jessica Liberty, Freeman Infection Preventionist, discuss how VigiLanz is helping them automatically track important trends in drugs, dosage, and kidney function.

By Gretchen Bolander, KSN Fourstates Homepage

 

You can read the full article on KSN Fourstates Homepage.

 

 

Transcript:

Keeping an eye on every patient in the hospital is more than a full time job. But some digital help is making sure patients are getting the smallest effective dose and steering clear of infections.

Adrienne Carey, Clinical Pharmacist, said, “It’s a data mining software program that we use in the pharmacy, our inpatient pharmacy, and it looks at all our in patients in the hospital.”

It’s called Vigilanz and it keeps tracks of important trends in drugs, dosage, and kidney function.

“It brings all those stuff to our attention in real time, there’s rules we build to help us catch some of those scenarios that we want to know about so we can intervene in a timely fashion.”

Before Vigilanz, it was a manual process.

“We would run a report out of our health info system to get a list of patients that are on a list of drugs and after that we would go into each electronic medical record or paper chart and dig to find what is their kidney function, is this the right dose for them, is this the right antibiotic for them, have they been vaccinated?”

Vigilanz can play a role in a wide range of cases, including the pandemic.

Jessica Liberty, Freeman Infection Prev.,said, “Covid is one of our activations we have a rule built in for that.”

Preventing infection is another role that Vigilanz helps with.

“You can imagine — we have 250 – 300 patients every day.”

Gathering that information and flagging areas of potential concern, helping patients get better and get home.

 

Vigilanz Offers COVID-19 Vaccine Management Solution Free to Customers | Healthcare IT Today

VigiLanz, a clinical surveillance company, announced the launch of a new mass vaccination support software. The company is offering Vigilanz Vaccinate free to its existing customers to help frontline healthcare teams stay safe.

I had the chance to sit down with Stacy Pur, Vice President of Product Development at Vigilanz to find out more about their product and to talk through some of the unique challenges of these early vaccines.

Why Free?

“The COVID-19 issue is personal—at VigiLanz, we have had employees and family members contract COVID-19 and require medical intervention,” said David Goldsteen, VigiLanz’s CEO. “We are so grateful for the amazing care healthcare teams are delivering across the country, and we wanted to do something to help. It was important to us to offer this tool [Vigilanz Vaccinate] to current customers for free to help them and their frontline healthcare teams stay safe during this extremely challenging global pandemic. It’s the right thing to do.”

You can read more of this article on Healthcare IT Today.

VigiLanz Launches New Software for Hospitals to Rapidly Deploy and Manage COVID-19 Mass Vaccination Events for Healthcare Workers

VigiLanz Vaccinate helps hospitals manage their COVID-19 risk, reduce vaccine waste, and automate data collection for CDC and state reporting

MINNEAPOLIS – Dec. 16, 2020 – VigiLanz, a clinical surveillance company, today announced the launch of a new mass vaccination support software, built on its leading enterprise software platform. VigiLanz Vaccinate provides end-to-end management of the entire vaccination process, enabling hospitals to maximize the success of mass vaccination events for healthcare workers. Especially critical now, as hospitals seek to protect staff members and patients from COVID-19 transmission, VigiLanz Vaccinate can also be used to manage annual influenza vaccination and other events. Current customers are being given priority access to the software, at no cost.

“It’s critical for hospitals to rapidly roll out the COVID-19 vaccine to staff—not only to keep frontline healthcare workers safe, but also to protect their families and the patients they work with until the vaccine is available to everyone,” said Stacy Pur, VigiLanz’s VP of Product Development. “The COVID-19 vaccine presents some unique challenges for mass vaccination events, as it expires quickly once thawed and requires two doses spaced at specific intervals. VigiLanz Vaccinate was designed to help manage this process, ensuring the maximum number of staff receive the vaccine as efficiently as possible.”

VigiLanz Vaccinate streamlines vaccine administration and management by making it easy for staff to register and provide consent, while automating workflows for program administrators. Its real-time insights into volume needs reduce vaccine waste, while analytics give visibility into vaccination and immunity rates at the individual, department, hospital, and system-level. The software issues automated reminders to healthcare staff to register and attend appointments for both vaccine doses, and report any side effects. In addition, it collates data for critical reporting back to the Centers for Disease Control (CDC), Vaccine Adverse Event Reporting System (VAERS), and the state, for immunity rates and any adverse side effects.

“The COVID-19 issue is personal—at VigiLanz, we have had employees and family members contract COVID-19 and require medical intervention,” said David Goldsteen, VigiLanz’s CEO. “We are so grateful for the amazing care healthcare teams are delivering across the country, and we wanted to do something to help. We’re proud of this demonstration of innovation and agility from our product team. When the pandemic hit, we created COVID Quick Start, a software module to help hospitals quickly implement a COVID-19 infection prevention solution. Now, with VigiLanz Vaccinate, we’ve rapidly developed and deployed an offering that our team saw a critical need for—helping frontline healthcare workers get vaccinated against COVID-19 as quickly and efficiently as possible. It was important to us to offer this tool to current customers for free to help them and their frontline healthcare teams stay safe during this extremely challenging global pandemic. It’s the right thing to do.”

VigiLanz is prioritizing current customer implementations to ensure their needs are met, with plans to accept future-customer inquiries as early as January 2021. Please direct requests to vaccinate@vigilanzcorp.com, and learn more at Vigilanzcorp.com/vaccinate.

 

###

 

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

 

Media Contact
Vanessa Ulrich
(410) 534.1161
vulrich@sage-growth.com

 

VigiLanz Announces Winners of 2020 Vigi Awards

Seven hospital systems are recognized for their outstanding commitments to patient safety and success in implementing clinical surveillance programs

 

MINNEAPOLIS – Nov. 18, 2020 – VigiLanz, a clinical surveillance company, today announced the winners of its annual Vigi Awards, which honor innovative hospitals around the country. This year, seven hospital systems are recognized for their exemplary patient safety achievements and their successful implementation of robust clinical surveillance programs.

VigiLanz’s annual Vigi Awards are designed to recognize how customers’ vigilance has contributed to healthier hospitals. VigiLanz customers have the opportunity to nominate individuals or teams who have gone above and beyond to drive optimal and innovative uses of VigiLanz to support patient care. Winners receive a donation to a charity of their choice. This year’s winners are:

Mount Sinai Beth Israel of the Mount Sinai Health System, New York, NY

Recognized for: Creating novel, new reports with VigiLanz leading to patient care improvements including a 75% decrease in the rate of catheter-associated urinary tract infections (CAUTIs) and a significant reduction in central line-associated bloodstream infection (CLABSIs), as well as significant cost savings and a faster infection prevention response to the first surge of COVID-19 patients in New York City.

EvergreenHealth, Kirkland, WA

Recognized for: Fully utilizing VigiLanz to make significant care improvements, including hospital-wide reductions in surgical site infections (SSIs) and standardized infection ratios (SIRs), reducing both by 75% over the last six months of 2019.

SCL Health, Broomfield, CO; SCL Health St. Vincent, Billings, MT

Recognized for:

  • Reducing the readmission rate of patients discharged from the emergency department with an infection through implementation of a new process, supported by VigiLanz, that enables pharmacists to quickly identify and reach out to discharged patients who might benefit from an alternate antibiotic
  • Faster identification of infections and precise enterprise-level monitoring, including the implementation of system-level healthcare-associated infection (HAI) dashboards that are instrumental to monitoring and comparing infection prevention performance across the full SCL enterprise

St. Bernards Medical Center, Jonesboro, AR

Recognized for: Innovative clinical surveillance initiatives that have had a widespread impact on patient care, including:

  • Decreasing the rate of vancomycin-induced acute kidney injury (AKI) from 10.34% to 4.79%
  • Decreasing broad spectrum gram-negative antibiotic days of therapy per 1000 patient days by 1%
  • Reducing the percentage of patients receiving more than 50 morphine milligram equivalents (MME) per day while admitted to the hospital by 3.27%

CHRISTUS Health Shreveport-Bossier, Shreveport, LA

Recognized for: Quickly implementing significant care improvements during the first year of VigiLanz use to achieve patient care and efficiency improvements, leading to more rapid identification of infections and enhanced compliance.

Health First Holmes Regional Medical Center, Melbourne, FL

Recognized for: New and innovative uses of VigiLanz that have brought significant benefits to patients, including:

  • Fewer incidences of hyperglycemia (62% vs 37%) in COPD patients
  • Fewer incidences of severe hypoglycemic events in patients with insulin (7% to 5%)
  • Optimized use of Kcentra

Northern Arizona Healthcare – Flagstaff Medical Center, Flagstaff, AZ

Recognized for: Using VigiLanz alerts to enhance care and manage drug supply shortages during the COVID-19 pandemic, including issuing alerts to relevant providers when:

  • Readmitted patients have a history of COVID-19
  • Key medications are ordered, such as Hydroxychloroquine and Remdesivir
  • Critical medications in short supply are ordered

 

“We were among the first and hardest hit hospitals by COVID-19,” said Kristen Bamberg, Lead Critical Care Pharmacist, Northern Arizona Healthcare. “We worked with VigiLanz to be forward thinking about how to tackle this challenge while supporting our pharmacists, providers, nurses, and patients. This enabled us to be nimble enough to work through countless therapeutic and workflow issues in real time. It’s an honor to be recognized by VigiLanz for our dedication to improving patient care.”

“We are incredibly proud of these hospital organizations for their achievements,” said Erik Johnson, VigiLanz’s Chief Commercial Officer. “Their improvements in patient safety, outcomes, and cost savings are exactly why we exist as an organization. We’re thrilled to recognize this year’s Vigi Award winners and inspire others through their success. To the winners – thank you for allowing VigiLanz to be part of your success.”

Learn more about this year’s Vigi Award winners here.

 

###

 

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

 

Media Contact

Vanessa Ulrich

(410) 534.1161

vulrich@sage-growth.com

Hospital Patient Safety Report: Infection Prevention Findings

To better understand the state of hospital patient safety and the biggest opportunities for improvement, VigiLanz commissioned Sage Growth Partners, a healthcare consultancy, to conduct an independent survey of 100 hospital and health system leaders in February 2020.

View the full report here.

This infographic highlights some of the most noteworthy infection prevention-related survey findings. The infographic reveals:

  • How hospital leaders rate their infection prevention efforts
  • Where infection prevention falls on their list of top safety priorities
  • How they are using technology to support their efforts

Podcast: Top Patient Safety Considerations for Hospitals as Flu Season Approaches

Tips for Health Systems

Stacy Pur, Vice President of Product Development at VigiLanz, shares her unique perspective on the challenges facing hospital systems as a result of the pandemic, including the impact on ICU nurses and hospital staff. In this conversation with Integrated Healthcare Executive, she shares how hospitals can increase patient safety, curb infection rates, and address flu season as it begins.

Riverside University Health System Uses VigiLanz for NICU Antimicrobial Stewardship

Customer Profile 

Riverside University Health System Medical Center (RUHS), a 439-bed facility in Moreno Valley, California, is committed to delivering exceptional care—and its quality performance reflects that commitment. Recognized by The Joint Commission as a top performer on key quality measures, RUHS has received awards from the American Heart Association/American Stroke Association. It is also recognized as a Baby Friendly Hospital by the World Health Organization and the United Nations Children’s Fund.

Challenge

As part of its commitment to providing optimal patient care, RUHS participates in the California Perinatal Quality Care Collaborative, a statewide network of California’s neonatal intensive care units (NICUs) and high risk infant follow-up clinics. In 2016, the collaborative launched an antibiotic stewardship (ASP) initiative with 28 NICUs, including RUHS.

At that time, RUHS had an antimicrobial stewardship program (ASP) for all patients, but it did not have a program that was focused solely on pediatric and NICU patients. “As we looked more closely at the younger patient population, we realized there was room for improvement in this area,” said Nikita Patel, Assistant Director of Pharmacy–Clinical Programs & Quality Improvement at RUHS.

She noted that, while there are established clinical practice guidelines for neonatal early onset sepsis management, they can contribute to higher antibiotic use—sometimes unnecessarily.

“If a baby has an active infection the first two to three days of life, the mortality outcomes are staggering and antibiotic use can be life-saving,” said Patel. “But unnecessary antibiotic use can disrupt a baby’s gut microbiome and impact their long-term immune response. This puts them at a higher risk of developing chronic diseases like asthma, and can lead to antibiotic resistance.”

Solution

RUHS turned to VigiLanz to support its efforts to optimize antibiotic use among pediatric and NICU patients. The clinical surveillance solution—which continuously gathers information from the medical center’s EMR and other sources, analyzes that data in real time, and provides meaningful insights to healthcare providers—enables pharmacists to view robust antimicrobial utilization reports. “The reports help us continuously monitor antimicrobial use and assess prescribing trends,” said Patel.

VigiLanz also provides relevant healthcare providers with real-time alerts that promote ASP in the NICU. These alerts include:

  • 48-hour antibiotic timeouts that enable NICU pharmacists to review information and recent lab results on relevant patients.
  • Positive lab results, so that pharmacists more quickly review critical labs and make appropriate medication change recommendations or antibiotic de-escalation.
  • Pharmacokinetic monitoring alerts, so that pharmacists can immediately make recommendations regarding dosage changes.
“I can’t emphasize enough how valuable VigiLanz is for us. It helps drive timely and important patient care interventions and improves our efficiency and documentation.” – Nikita Patel, Assistant Director of Pharmacy – Clinical Programs & Quality Improvement, RUHS

Outcomes

The new approach to ASP at RUHS has had a significant positive effect on patient care, said Patel. “I can’t emphasize enough how valuable VigiLanz is for us,” she said. “It helps drive timely and important patient care interventions and improves our efficiency and documentation.”

Two noteworthy outcomes of the new approach include:

  • A 37% decrease in NICU antibiotic utilization between March 2017 and March 2018. Importantly, that 37% drop has also been sustained since 2018.
  • More than 90% compliance with 48-hour antibiotic timeouts for all patients admitted to the NICU and initiated on antimicrobials.

VigiLanz also saves pharmacists time, which also benefits patient care, said Patel. “We no longer have to manually review patient lists and data every day,” she explained. “VigiLanz automatically sorts relevant data for us and alerts us when there’s a potential problem or when there’s something new to review. That helps us intervene more quickly and spend more time on other patient care improvement initiatives.”

 

To learn more about how VigiLanz helps hospitals improve their patient safety and clinical surveillance, visit https://vigilanzcorp.com/ today.

Freeman Health System Uses VigiLanz to Enhance MRSA Screening, Reduce Vancomycin Use

Customer Profile

Freeman Health System, a 485-bed, three-hospital system in Joplin, Missouri, serves an area of 450,000 people across Missouri, Arkansas, Kansas, and Oklahoma. It is the #1 hospital in Southwest Missouri and the #4 hospital in Missouri, according to U.S. News & World Report.

Challenge

Hospitals across the country are fighting to combat antibiotic overuse, resistance, and unwanted side effects, but many are struggling to implement new and effective workflows that help meet these goals. Much of the challenge boils down to speed and efficiency—hospitals need to identify antibiotic overuse more quickly, and intervene sooner when it does occur.

Freeman Health System is no exception to the challenges associated with antimicrobial stewardship (ASP), and it was looking for a way to improve its ASP processes, particularly related to vancomycin use among patients with pneumonia.

“Data shows that 98 percent of the time, a negative MRSA screen for a patient with pneumonia means that a patient does not have MRSA-pneumonia, and their empiric vancomycin therapy can safely be discontinued,” said Adrienne Carey, PharmD, BCPS, Clinical Pharmacist and Data Mining Program Manager at Freeman Health System. “We wanted to streamline our MRSA screening process so that we could more quickly identify if a MRSA screen is negative, and therefore, discontinue vancomycin use sooner.”

Solution

Freeman Health System’s antibiotic stewardship team had already changed the health system’s pneumonia pathway orders to ensure all patients who came into the ER automatically received a nasal screen for MRSA.

“Our pharmacy department was tasked with educating physicians about the change and with contacting them with the results,” said Carey. “The goal was to de-escalate patients’ antibiotics more quickly.”

The problem was that results were not always communicated quickly to pharmacists, so there was sometimes a delay in identifying patients whose vancomycin therapy could be discontinued.

Freeman Health System turned to VigiLanz to help, working with the VigiLanz clinical support team to create a negative MRSA screen rule within the system. Now, whenever a patient prescribed vancomycin has a negative MRSA screen and no other cultures are positive for MRSA, the pharmacy team and infectious disease physician receive an alert in real time.

“Before implementing the VigiLanz rule, we had to manually run reports through our health information system to view all patients on vancomycin, then check each patient’s microbiology results to see if they had been screened for MRSA,” said Carey. “That took a lot of time.”

Now, pharmacists and physicians can more quickly discontinue vancomycin use and switch to an alternate antibiotic when appropriate, she explained. “We are not leaving our patients on vancomycin any longer than necessary.”


Adrienne Carey, PharmD, BCPS describes real-time alerts helping pharmacists

Outcomes 

In the first six months since November 2018, when the new workflow was implemented, Freeman Health System’s pharmacists worked with physicians to discontinue vancomycin therapy in 70 patients.

Other key benefits of the new approach include:

  • Time savings for pharmacists
  • Time savings for nurses by reducing doses and drawing fewer labs
  • Monetary savings by reducing unneeded antibiotics
  • Reduced risk of infection through an IV route since IV lines are discontinued sooner due to de-escalation
  • Fewer medication side effects
  • Less chance for antibiotic resistance
  • Improved patient satisfaction due to fewer medications being administered
  • Shorter lengths of stay

“Building this rule and receiving immediate alerts from VigiLanz is helping us better identify all patients who qualify to have their therapy de-escalated and do so in a timely fashion,” said Carey. “We have also seen a trend toward less vancomycin usage overall.”

Related Resource: